Semaglutide, a peptide-based compound, has been under clinical investigation for its potential role in weight management among obese individuals. A multicentre, randomised, open-label, parallel, positive-controlled Phase 3 clinical study was conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to evaluate the efficacy and safety of their Semaglutide injection (TQF3510) compared with the established drug Wegovy® (semaglutide).

Study Design and Objectives

The trial enrolled obese subjects with a body mass index (BMI) of 28 kg/m2 or higher. Participants were randomly assigned in a 1:1 ratio to receive either the experimental Semaglutide injection or Wegovy®. The primary endpoint was the percentage of weight loss at 44 weeks relative to baseline. Equivalence testing was employed to determine if the new formulation's effects fell within a pre-specified margin (±4.16%) compared to Wegovy®.

Key Findings and Analysis

A meta-analysis of multiple registration studies of Wegovy® informed the equivalence threshold. The study assumed no overall difference in weight loss between groups and used the standard deviation from the reference drug for statistical calculations. Although the detailed results have not been publicly disclosed, the study was completed, marking an important step in assessing alternative semaglutide formulations for obesity management.

Context and Implications

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been widely studied for metabolic effects. This clinical trial contributes to the growing body of research evaluating biosimilar or alternative peptide therapies. It is important to note that such studies are conducted under stringent regulatory frameworks, and findings must be interpreted with caution until peer-reviewed publication and regulatory approval.

For those interested in peptides and related compounds, the BuyOnlineMedication.com platform offers educational resources and a community forum at Peptide Pen Community to discuss research-use peptides and product literacy. The shop provides access to research-grade peptides for laboratory and investigational purposes.

Research-Use Disclaimer

Products discussed herein are intended for research use only and not for human consumption, diagnosis, or treatment. Clinical trial data should be considered preliminary until validated by regulatory authorities and published in peer-reviewed journals.

Explore more through Peptide Pen Community.